Limitations: - CT-388 data is early stage (Phase 1/2), making comparisons to late-stage or approved competitors regarding efficacy somewhat premature.- Competitor trials involving semaglutide and tirzepatide are based on larger patient populations and longer duration, providing a more robust data set validating their therapeutic benefit.- Weight loss achieved with GLP-1 receptor agonists such as semaglutide and the dual GLP-1/GIP receptor agonist tirzepatide appear greater than the weight loss observed to date with CT-388.- Competitor agents have established cardiovascular benefits and substantial net weight reductions, which set a high efficacy bar for CT-388 to meet or exceed.- Incretin therapies are challenged by supply shortages and complex titration schemes
Now, Winfrey feels better than ever
Thorner, M., Rochiccioli, P., Colle, M., Lanes, R., Grunt, J., Galazka, A., Landy, H., Eengrand, P., & Shah, S
Here are some of the key players you'll want on your team
plan changes require active contact with the care team and don't happen automatically
Combination peptide protocols Stacking copper peptides with other peptide types may address wrinkles through multiple mechanisms simultaneously
